U.S. Markets

Novo Nordisk’s (NOVOB DC/NVO) Sogroya receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner syndrome

ORIGINAL · NewsquawkNovo Nordisk’s (NOVOB DC/NVO) Sogroya receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner syndrome
StockNow breaking-news AI analysis

The FDA approval makes Sogroya the first and only once-weekly, long-acting growth hormone for children with Turner syndrome.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more